The BEACON study, which spans over 20 sites across the United States, evaluates the safety and efficacy of SL1002, a targeted perineural chemoneurolytic injection powered by the company’s proprietary CYCLOPHLEX technology. With enrollment closed as of October 2, 2026, researchers expect to release topline data in the second quarter of 2027. CEO Dave Penake noted that the trial’s progress relies heavily on the return of investigators who previously participated in the company’s Phase II COMPASS study.

Simultaneously, the pharmaceutical firm is preparing for an End-of-Phase II meeting with the FDA to map out a development program for using SL1002 to treat spasticity. This secondary indication represents a broader ambition for the compound, which remains investigational and is not yet approved for any clinical use. Saol Therapeutics, which maintains operations in Roswell, Dublin, and Hamilton, plans to initiate a second Phase III study for knee pain to support future regulatory filings, aiming to address the limited non-opioid options currently available to patients.